Salmon Dominique, Robain Mathieu, Rockstroh Jurgen K, Benhamou Yves
Infectious Diseases Unit, Cochin Hospital, René Descartes University, Paris V, 27, rue du Faubourg Saint Jacques, 75014 Paris, France.
J Hepatol. 2006;44(1 Suppl):S2-5. doi: 10.1016/j.jhep.2005.11.034. Epub 2005 Dec 5.
The First European Consensus Conference on the Treatment of Chronic Hepatitis B and C in HIV Co-infected Patients aimed to produce recommendations that could be applied across Europe. However, some important differences exist around Europe, in terms of access to treatment and tests for monitoring. This short survey of 24 European countries showed that access to anti-HCV treatment is low (approximately 10%) in patients with HCV/HIV co-infection--generally access is higher in Western Europe than in Eastern or Northern Europe. This low use of anti-HCV therapy is not a result of poor availability (of drugs or virological tests), which are available in all countries surveyed. Recently published trials in co-infected patients and the outcome from this Consensus Conference will hopefully lead to wider access to anti-HCV therapy and better management of co-infected patients across Europe.
第一届欧洲艾滋病毒合并感染患者慢性乙型和丙型肝炎治疗共识会议旨在制定可在欧洲各地应用的建议。然而，在欧洲各地，在获得治疗和监测检测方面存在一些重要差异。这项对24个欧洲国家的简短调查显示，丙型肝炎病毒/艾滋病毒合并感染患者中抗丙型肝炎病毒治疗的可及性较低（约10%）——一般来说，西欧的可及性高于东欧或北欧。抗丙型肝炎病毒疗法的低使用率并非药物或病毒学检测供应不足所致，在所有接受调查的国家都有这些资源。最近发表的合并感染患者试验以及本次共识会议的结果有望在欧洲各地实现抗丙型肝炎病毒疗法的更广泛可及性，并改善合并感染患者的管理。
